CAR-NK therapy development combines chimeric antigen receptor engineering with natural killer cells to target tumors with enhanced cytotoxicity and reduced risk of graft-versus-host disease. This platform supports cell sourcing, vector design, functional validation, and preclinical evaluation for off-the-shelf immunotherapy solutions.
